Egrifta Sv
Product manufactured by Theratechnologies Inc.
Indications and Purposes
| 1 Indications And Usage Egrifta Sv Is Indicated For The Reduction Of Excess Abdominal Fat In Hiv-Infected Adult Patients With Lipodystrophy. Limitations Of Use: Long-Term Cardiovascular Safety Of Egrifta Sv Has Not Been Established. Consider Risk/benefit Of Continuation Of Treatment In Patients Who Have Not Had A Reduction In Visceral Adipose Tissue. Egrifta Sv Is Not Indicated For Weight Loss Management As It Has A Weight Neutral Effect. There Are No Data To Support Improved Compliance With Anti-Retroviral Therapies In Hiv-Positive Patients Taking Egrifta Sv. Egrifta Sv Is A Growth Hormone Releasing Factor (Ghrf) Analog Indicated For The Reduction Of Excess Abdominal Fat In Hiv-Infected Adult Patients With Lipodystrophy. ( 1 ) Limitations Of Use: Long-Term Cardiovascular Safety Of Egrifta Sv Has Not Been Established. ( 1 ) Not Indicated For Weight Loss Management. ( 1 ) There Are No Data To Support Improved Compliance With Anti-Retroviral Therapies In Hiv-Positive Patients Taking Egrifta Sv. ( 1 ) |
All Formulated Excipients (0 Total)
None
Active Ingredients ( 1 Total)
| Name | Structure | ZINC ID(s) |
|---|---|---|
| 1. Tesamorelin |